In Vivo CAR-T Therapy
Phase 1Cell therapy
In Vivo CAR-T Therapy is one of 15 biologic programs targeting Graves disease. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Graves Disease
#DrugCompanyPhaseTrials
1Tapazole
VViking Therapeutics, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Synthroid
IInstitut Jerome Lejeune
Approved
Efgartigimod PH20 SC
ArgenxPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
IMVT-1402
IImmunovant Sciences GmbH
Phase 2
BHV-1300
BBiohaven Therapeutics Ltd.
Phase 3
Allogeneic CAR-T
TThe First Affiliated Hospital with Nanjing Medical University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for In Vivo CAR-T Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- SShanghai Zhongshan Hospital